浏览全部资源
扫码关注微信
芦可替尼对慢性移植物抗宿主病患者的疗效及安全性研究
Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease
- 第三军医大学学报 2019年41卷第23期 页码：2290-2295
- 作者机构：
- 作者简介：
- 基金信息：
DOI：10.16016/j.1000-5404.201906230
中图分类号：收稿：2019-06-26，
纸质出版：2019-12-25
- 稿件说明：
移动端阅览
黄小丽, 刘林, 袁忠涛, 等. 芦可替尼对慢性移植物抗宿主病患者的疗效及安全性研究[J]. 第三军医大学学报, 2019,41(23):2290-2295.
Xiaoli HUANG, Lin LIU, Zhongtao YUAN, et al. Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease[J]. Journal of Third Military Medical University, 2019, 41(23): 2290-2295.
黄小丽, 刘林, 袁忠涛, 等. 芦可替尼对慢性移植物抗宿主病患者的疗效及安全性研究[J]. 第三军医大学学报, 2019,41(23):2290-2295. DOI： 10.16016/j.1000-5404.201906230.
Xiaoli HUANG, Lin LIU, Zhongtao YUAN, et al. Clinical efficacy and safety of ruxolitinib in treatment of chronic graft versus host disease[J]. Journal of Third Military Medical University, 2019, 41(23): 2290-2295. DOI： 10.16016/j.1000-5404.201906230.
摘要
Abstract
Objective
2
To study the clinical efficacy and safety of ruxolitinib in the treatment of chronic graft versus host disease (cGVHD).
Methods
2
We collected the clinical data of 42 cGVHD patients after receiving allogeneic hematopoietic stem cell transplantation from July 1
2016 to February 1
2019 in our hospital. There were 2 specific treatment regimens. For the patients diagnosed with the skin
mouth
eyes
joints or genital tract involvement
5 mg/d ruxolitinib was given (when the patient weighs less than 25 kg
or ruxolitinib is administered in combination with a potent CYP3A4 inhibitor or fluconazole
the total dose is halved) on the basis of the original immunosuppressant therapy. For those diagnosed with lung
liver or gastrointestinal tract involvement
5 mg/d ruxolitinib and 1 mg/(kg·d) methylprednisolone were given on the basis of the original immunosuppressant therapy. The clinical efficacy was evaluated in 1 and 3 month after treatment. Peripheral blood test
coagulation function
copy number of human cytomegalovirus and chest CT scanning were performed every week.
Results
2
Among the 42 cGVHD patients
overall response rates (ORR) were 85.7% (36/42) and 95.2% (40/42) at 1 month and 3 months after treatment
respectively. In the process of this study
6 patients developed pulmonary infection
and 4 patients experienced bleeding events. There were 12 patients having human cytomegalovirus and epstein-barr virus infection or the virus copy number being continued to rise. Bone marrow suppression at grade of Ⅰ~Ⅱ presented in 8 patients. During the follow-up period of 4 (1~19) months
no one patient was lost
and 4 patients (9.5%
4/42) died
due to leukemia recurrence
pulmonary infection and poor control of cGVHD.
Conclusion
2
Ruxolitinib has significant efficacy in the treatment of cGVHD
with low adverse reactions and preventable and tolerable effects.
关键词
Keywords
references
PAVLETIC S Z MARTIN P LEE S J Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. response criteria working group report Biol Blood Marrow Transplant 2006 12 3 252 266 10.1016/j.bbmt.2006.01.008 PAVLETIC S Z, MARTIN P, LEE S J, et al . Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. response criteria working group report[J ] . Biol Blood Marrow Transplant, 2006, 12(3): 252-266. DOI:10.1016/j.bbmt.2006.01.008.
ASSOUAN D LEBON D CHARBONNIER A Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus -host disease Br J Haematol 2018 181 5 687 689 10.1111/bjh.14679 ASSOUAN D, LEBON D, CHARBONNIER A, et al . Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus -host disease[J ] . Br J Haematol, 2018, 181(5): 687-689. DOI:10.1111/bjh.14679.
MARTIN P J STORER B E INAMOTO Y An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease Blood 2017 130 3 360 367 10.1182/blood-2017-03-775767 MARTIN P J, STORER B E, INAMOTO Y, et al . An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease[J ] . Blood, 2017, 130(3): 360-367. DOI:10.1182/blood-2017-03-775767.
JAGLOWSKI S M BLAZAR B R How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD Blood Adv 2018 2 15 2012 2019 10.1182/bloodadvances.2018013060 JAGLOWSKI S M, BLAZAR B R. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD[J]. Blood Adv, 2018, 2(15): 2012-2019. DOI:10.1182/bloodadvances.2018013060.
ZEISER R BLAZAR B R Pathophysiology of chronic graft-versus-host disease and therapeutic targets N Engl J Med 2017 377 26 2565 2579 10.1056/nejmra1703472 ZEISER R, BLAZAR B R. Pathophysiology of chronic graft-versus-host disease and therapeutic targets[J]. N Engl J Med, 2017, 377(26): 2565-2579. DOI:10.1056/nejmra1703472.
IM A HAKIM F T PAVLETIC S Z Novel targets in the treatment of chronic graft-versus-host disease Leukemia 2017 31 3 543 554 10.1038/leu.2016.367 IM A, HAKIM F T, PAVLETIC S Z. Novel targets in the treatment of chronic graft-versus-host disease[J]. Leukemia, 2017, 31(3): 543-554. DOI:10.1038/leu.2016.367.
MASCARENHAS J HOFFMAN R Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis Clin Cancer Res 2012 18 11 3008 3014 10.1158/1078-0432.CCR-11-3145 MASCARENHAS J, HOFFMAN R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis[J]. Clin Cancer Res, 2012, 18(11): 3008-3014. DOI:10.1158/1078-0432.CCR-11-3145.
SPOERL S MATHEW N R BSCHEIDER M Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease Blood 2014 123 24 3832 3842 10.1182/blood-2013-12-543736 SPOERL S, MATHEW N R, BSCHEIDER M, et al . Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease [J ] . Blood, 2014, 123(24): 3832-3842. DOI:10.1182/blood-2013-12-543736.
JAGASIA M ZEISER R ARBUSHITES M Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials Immunotherapy 2018 10 5 391 402 10.2217/imt-2017-0156 JAGASIA M, ZEISER R, ARBUSHITES M, et al . Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials[J ] . Immunotherapy, 2018, 10(5): 391-402. DOI:10.2217/imt-2017-0156.
JAGASIA M H GREINIX H T ARORA M National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report Biol Blood Marrow Transplant 2015 21 3 389 401.e1 10.1016/j.bbmt.2014.12.001 JAGASIA M H, GREINIX H T, ARORA M, et al . National institutes of health consensus developm ent project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report[J ] . Biol Blood Marrow Transplant, 2015, 21(3): 389-401.e1. DOI:10.1016/j.bbmt.2014.12.001.
李 小平 张 曦 慢性移植物抗宿主病二线治疗进展 中华血液学杂志 2019 40 2 160 163 10.3760/cma.j.issn.0253-2727.2019.02.014 李小平, 张曦.慢性移植物抗宿主病二线治疗进展[J].中华血液学杂志, 2019, 40(2):160-163.DOI:10.3760/cma.j.issn.0253-2727.2019.02.014.
LI X P ZHANG X Progress in second-line treatment of chronic graft-versus-host disease Chin J Hematol 2019 40 2 160 163 10.3760/cma.j.issn.0253-2727.2019.02.014 LI X P, ZHANG X. Progress in second-line treatment of chronic graft-versus-host disease[J]. Chin J Hematol, 2019, 40(2):160-163.DOI:10.3760/cma.j.issn.0253-2727.2019.02.014.
MA H H LU C S ZIEGLER J Absence of Stat1 in donor CD4 + T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice J Clin Invest 2011 121 7 2554 2569 10.1172/JCI43706 MA H H, LU C S, ZIEGLER J, et al . Absence of Stat1 in donor CD4 + T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice[J ] . J Clin Invest, 2011, 121(7): 2554-2569. DOI:10.1172/JCI43706.
MA H H ZIEGLER J LI C L Sequential activation of inflammatory signaling pathways during graft-versus-host disease(GVHD): early role for STAT1 and STAT3 Cell Immunol 2011 268 1 37 46 10.1016/j.cellimm.2011.01.008 MA H H, ZIEGLER J, LI C L, et al . Sequential activation of inflammatory signaling pathways during graft-versus-host disease(GVHD): early role for STAT1 and STAT3[J ] . Cell Immunol, 2011, 268(1): 37-46. DOI:10.1016/j.cellimm.2011.01.008.
BLAZAR B R MURPHY W J ABEDI M Advances in graft-versus-host disease biology and therapy Nat Rev Immunol 2012 12 6 443 458 10.1038/nri3212 BLAZAR B R, MURPHY W J, ABEDI M. Advances in graft-versus-host disease biology and therapy[J]. Nat Rev Immunol, 2012, 12(6): 443-458. DOI:10.1038/nri3212.
HEINE A HELD S A DAECKE S N The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo Blood 2013 122 7 1192 1202 10.1182/blood-2013-03-484642 HEINE A, HELD S A, DAECKE S N, et al . The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo [J ] . Blood, 2013, 122(7): 1192-1202. DOI:10.1182/blood-2013-03-484642.
TAKAHASHI S HASHIMOTO D HAYASE E Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease Blood 2018 131 18 2074 2085 10.1182/blood-2017-06-792614 TAKAHASHI S, HASHIMOTO D, HAYASE E, et al . Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease[J ] . Blood, 2018, 131(18): 2074-2085. DOI:10.1182/blood-2017-06-792614.
CHOI J ZIGA E D RITCHEY J IFNγR signaling mediates alloreactive T-cell trafficking and GVHD Blood 2012 120 19 4093 4103 10.1182/blood-2012-01-403196 CHOI J, ZIGA E D, RITCHEY J, et al . IFNγR signaling mediates alloreactive T-cell trafficking and GVHD[J ] . Blood, 2012, 120(19): 4093-4103. DOI:10.1182/blood-2012-01-403196.
CHOI J COOPER M L ALAHMARI B Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect PLoS ONE 2014 9 10 e109799 10.1371/journal.pone.0109799 CHOI J, COOPER M L, ALAHMARI B, et al . Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect[J ] . PLoS ONE, 2014, 9(10): e109799. DOI:10.1371/journal.pone.0109799.
CARNITI C GIMONDI S VENDRAMIN A Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects Clin Cancer Res 2015 21 16 3740 3749 10.1158/1078-0432.CCR-14-2758 CARNITI C, GIMONDI S, VENDRAMIN A, et al . Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects[J ] . Clin Cancer Res, 2015, 21(16): 3740-3749. DOI:10.1158/1078-0432.CCR-14-2758.
ZHONG J YANG P MUTA K Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock PLoS ONE 2010 5 3 e9593 10.1371/journal.pone.0009593 ZHONG J, YANG P, MUTA K, et al . Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock[J ] . PLoS ONE, 2010, 5(3): e9593. DOI:10.1371/journal.pone.0009593.
ZEISER R BURCHERT A LENGERKE C Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey Leukemia 2015 29 10 2062 2068 10.1038/leu.2015.212 ZEISER R, BURCHERT A, LENGERKE C, et al . Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey[J ] . Leukemia, 2015, 29(10): 2062-2068. DOI:10.1038/leu.2015.212.
MORI Y IKEDA K INOMATA T Ruxolitinib treatment for GvHD in patients with myelofibrosis Bone Marrow Transplant 2016 51 12 1584 1587 10.1038/bmt.2016.256 MORI Y, IKEDA K, INOMATA T, et al . Ruxolitinib treatment for GvHD in patients with myelofibrosis[J ] . Bone Marrow Transplant, 2016, 51(12): 1584-1587. DOI:10.1038/bmt.2016.256.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
